Top of page Skip navigation

    Register today...


    Join us for some great networking


8.00 - 09.00

Registration, networking, breakfast and partnering

9.00 - 09.15

Welcome, BIA Update and launch of Celebrate report

Steve Bates
Chief Executive Officer, BIA

View from the US

James C Greenwood
President and Chief Executive Officer, BIO

9.15 - 09.40

Opening Keynote Presentation

Simon Stevens
Chief Executive Officer, NHS England

9.40 - 10.20

Type 1 Diabetes: The UK Bioscience ecosystem in action

Aisling Burnand MBE
Chief Executive Officer, Association of Medical Research Charities

Rachel Connor
Director of Research Partnerships, JDRF

Dr Sarah Howell
Chief Executive Officer, Arecor

Patient Advocate - Sarah Liveing

10.20 - 10.50

BBSRC Innovator of the Year

Professor Tom Brown
University of Oxford

Tom is the inventor on several patents that have led to commercial products in the biotech field, and he has collaborated with industry to develop new methods of genetic and forensic analysis based on fluorescent probes including Scorpions and HyBeacons. Scorpion technology has been used to stratify cancer patients to inform on clinical decisions (personalised medicine) and HyBeacons are used in diagnostic and forensic applications. He has also co-founded three successful companies based on innovations in the nucleic acid field (Oswel, ATDBio, Primer Design). Recently Tom has developed new chemical methods to join together DNA strands (click ligation) with potential applications in drug discovery and synthetic biology. This presentation will focus on the history of Tom’s various commercial activities, the challenges faced along the way, the approaches he took to overcome them and future plans.

10.50 - 11.30

 Refreshments, networking, exhibition and partnering

11.30 - 13.00

Parallel Tracks

11.30 - 12.15

Eleanor Davies-Colley Lecture Theatre

100,000 Genomes Project - accelerating the development of new diagnostics and personalised care

Representatives from the 100,000 Genomes project update us on the latest developments and explain how the project will accelerate new diagnostics and personalised care in being delivered.

Anthony Finbow
Executive Chairman, Eagle Genomics

Professor Tim Hubbard
Head of Genome Analysis, Genomics England and Prof of Bioinformatics, Kings College

Dr Ellen McDonagh  
Head of Curation, Genomics England

Dr Damien Smedley
Director of Genomic Interpretation and Associate Director of Bioinformatics, Genomics England

Council Room

Patent Box -  is it worth it?

Our expert panel will discuss the relevance and future of the Patent Box, along with practical guidelines for companies of all sizes. 

  • What are the benefits for businesses at different stages of corporate development?
  • How does Patent Box contribute to the UK’s attractiveness to foreign investors?
  • Changing environment between patent box and corporate tax
  • Scoping and deadlines – how to plan for 2017

Colin Hailey
Partner, Confluence Tax

Helen Clegg
Senior Tax Manager, AstraZeneca

Sarah Churton
International Tax Executive Director, EY

Mark Gallagher
Senior Manager, International Tax Services, EY


Vandervell Lecture Theatre
Stimulating a vibrant anti-microbial sector in the UK

In this session, led by experts from Public Health England and other key players, we address conclusions from the AMR Review and what is required in order to move these through to successful outcomes

  • England’s CMO has warned that in twenty years’ time we will have run out of antibiotics if we don’t act now
  • A vibrant and incentivised antimicrobial and diagnostic sector in collaboration with emerging economies will be vital to develop new antimicrobials and innovative tools to guide appropriate prescribing
  • GP practices and diagnostics are critical to the success of new antibiotics
  • International/cross-sector liaison and continuing R&D will be key to surveillance and stewardship


Dr David Rhodes
Deputy Director, Public Health England

Hala Audi
Head of AMR Reviw Team

Dr Vlad Hogenhuis
Senior Vice President and Head, Specialty Pharma Franchise, GlaxoSmithKline

Dr Peter Jackson
Executive Chairman, The AMR Centre

Dr Deborah O'Neil
Chief Executive and Scientific Officer, Novabiotics

Professor S.S. Vasan
Senior Business Development Manager, Public Health England

Professor Neil Woodford
Head of AMRHAI Reference Unit, Public Health England and Visiting/Honorary Professor, Imperial College, UCL and QMUL

12.15 - 13.00

Eleanor Davies-Colley Lecture Theatre

The next generation of talent – from boardroom to bench

The UK bioindustry believes that we must foster the next generation of leadership. At CEO fora and BIA panels over recent years it has supported the promotion, mentoring and celebration of emerging talent. It has also highlighted the role of the Board in owning the ‘senior talent agenda’. If the Board embraces this role, then it must also accept the responsibility to spawn the next generation of Board talent.

In his book ‘The Fish Rots from the Head: the crisis in our Boardrooms’ Bob Garratt describes the pivotal role of the Board. Research by RSA and others has highlighted a number of worrying trends in UK biotech boards that may limit their ability to guide their firms - and the millions invested in them - to future success. These include:

  • a lack of diversity
  • an over-reliance on the wisdom of years versus the vision of the next generation
  • ‘overboarding’ – where Board members are resident on large numbers of other similar ventures
  • a limited mix of skills coupled to a selection by friendship over a ‘fit-to-the-future’. These combinations can affect Boards’ ability to challenge the executive and scan the horizon for issues and opportunities that will secure the long term value of their companies

At this session we will present Real World data on the make-up of today’s UK private biotech boards. Panellists from public and private boards will then provide a SWOT analysis on their role, examine their opportunity to create next generation Boards and stimulate discussion on what we can all do to support the next generation leadership of our biotech industry.

Chris Molloy
Chief Executive Officer, RSA

Dr Ken Macleod

Brenda Reynolds
Chief Executive Officer, Calchan

Dr Denise Scots- Knight 
Chief Executive Officer and Founder, Mereo Biopharma Group

Carl Sterritt
Chief Executive Officer, Shield Therapeutics

Dr Ian Tomlinson
Chairman, Apollo Therapeutics and Stevenage Bioscience Catalyst and BIA Board

Council Room

How will UK bioscience be affected by the changing international IP landscape?

In this session, we explore how UK bioscience will be affected by the changing international IP landscape and whether harmonisation is achievable, or even desirable.

  • What opportunities are presented by Brexit, what will happen to Supplementary Protection Certificates and the Unified Patent Court?
  • How could recent US court rulings like Ariosa v. Sequenom affect your business?

Nicola Baker-Munton

Chief Executive Officer, Stratagem IPM

Brexit opportunities for UK bioscience IP: what will happen to the Unitary Patent?

Rowan Freeland
Partner, Intellectual Property, Simmons & Simmons

International IP harmonisation: The Sequenom vs. Ariosa ruling and how it could affect your business

Dr Hazel Ford
Partner, European Patent Attorney, Finnegan

Dr Erin Sommers

Associate, Finnegan

Vandervell Lecture Theatre

Stimulating a vibrant anti-microbial sector in the UK continues

13.00 - 14.15

Lunch, networking, exhibition and speed-partnering

14.15 - 15.45

Parallel Tracks

14.15 - 15.00

Eleanor Davies-Colley Lecture Theatre

Access to orphan medicines

This session will endeavour to bring delegates an update on developments in the orphan medicine and rare disease field, demystify the multiple routes for reimbursement in the UK and an opportunity to hear from a range of stakeholders from NICE to patient advocates and biotech companies that experienced the process.

Introduction from the Chair 
Alastair Kent OBE
Director, Genetic Alliance UK

Routes for reimbursement in the UK: Overview 
Sheela Upadhyaya 
Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE)

Industry experience - case study

Cystic fibrosis treatment in the UK and EU
Benjamin Gannon
Head of International Government Affairs, Vertex Pharmaceuticals

Panel Discussion / Q&A 
Speakers from this session will be joined by

Nathalie Moll
Secretary General, EuropaBio

Council Room

It’s not just tomorrow’s fish-and-chip paper - why effective media relations matters

Effective communications has never been more important than in today’s multi-faceted and fast-paced media environment and has the potential to significantly impact a company’s reputation for good or bad. Our panel will provide insight into effective media relations from those on both sides of the equation including journalists, companies and communicators.

Dr Chris Gardner
Partner, Consilium Strategic Communications

David Cox
Healthcare Sales, Panmure Gordon

John Milad
Chief Executive Officer and Founder, Quanta Dialysis Technologies

Tom Sheldon
Senior Press Manager, Science Media Centre

Dr Sukaina Virji
News Editor, SCRIP Intelligence

Vandervell Lecture Theatre

Lighting up biopharmaceutical discovery

Diamond Light Source is the UK’s synchrotron and one of the most advanced scientific facilities in the world.  By harnessing the power of electrons at near light speed it can be used to study a vast range of subject matter, from mapping targets for new cancer drugs to characterising medicines, as well as everything from fossils to jet engines and viruses to vaccines.

Porton Biopharma Limited (PBL) were the first company to use Diamond’s biological small angle X-ray scattering (bioSAXS) data collection and analysis service to characterise product variants and are proud to present a session focusing on what Diamond can do for bioscience.

Speakers will provide an overview of Diamond’s capabilities in life sciences, those who have used Diamond to investigate G protein-coupled receptors to develop treatments for CNS and Metabolic diseases, and from PBL who will describe how Diamond was used to provide evidence to regulatory authorities in support of a drug substance

Dr Trevor Marks
Director of Development, Porton BioPharma

Dr Zoë Cattell
Industrial Liaison Marketing Manager, Diamond Light Source

Dr Rob Cooke
Head of the Biomolecular Structure Department, Heptares Therapeutics

Dr David Gervais
Innovation Lead, Porton BioPharma

15.00 – 15.45

Access to orphan medicines continues

Council Room

Investment in UK – what will the landscape look like in the future?

Dr Allan Marchington
Senior Advisor, Apposite Capital

Dr Sam Fazeli
Head of Bloomberg Intelligence, EMEA; Senior Pharmaceutical Analyst Bloomberg Industries

Dr Hakan Goker
Senior Investment Director, MS Ventures

Dr Daniel Mahony
Partner, Polar Capital Partners

Dr Andy Richards CBE
Biotech Entrepreneur

Dr Robert Tansley
Investment Director, Healthcare, Cambridge Innovation Capital




15.45 - 16.15

Refreshments, networking, exhibition and speed-partnering

16.15 - 17.00

Innovation Showcase

Hear from five BIA member organisations on their new innovations and how their work can help improve the sector and healthcare of the future

Dr Will West
Executive Chairman, CellCentric and BIA Board

Dr Martin Pule
Founder and Chief Scientific Officer, Autolus

Cambridge Medical Robotics
Dr Martin Frost
Chief Executive Officer, Cambridge Medical Robotics

Gen2 Neuroscience
Dr Rick Livesey
Chief Executive Officer, Gen2 Neuroscience

Immodulon Therapeutics
Dr Linda Summerton
Chief Executive Officer, Immodulon Therapeutics

Orla Protein Technologies
Dr Dale Athey

Chief Executive Officer, Orla Protein Technologies

17.00 - 17.45

Brexit – where are we at and what next?

With Brexit foremost in the minds of the sector, this panel debate will highlight where the sector is at present, the work done so far and what’s next to ensure the EU transition for the bioscience community is coherent and seamless

Dr Jane Osbourn 
Vice President Research and Development, MedImmune and Chair, BIA

Steve Bates
Chief Executive Officer, BIA

Dr Harren Jhoti 
President and Chief Executive Officer, Astex Pharmaceuticals

Nathalie Moll
Director General, EuropaBio

Jo Pisani
Partner, Strategy&, PwC

17.45 - 17.50

Summary and Close

18.00 - 18.30

BIA AGM (BIA members Only)

18.30 - 21.00

BIA Autumn Reception - Connecting the bioscience community